Phase 3 clinical trials explained: what patients should know

What is a Phase 3 trial?

A Phase 3 study is designed to show whether a medical product gives a real treatment benefit to a specific group of patients, and it is sometimes called a pivotal study. It typically enrols 300 to 3,000 volunteers who already have the disease or condition being studied. The study usually lasts one to four years. In most cases, this is the last controlled research step before a regulatory authority is asked to decide whether a treatment can be marketed. That is one reason it is described as pivotal. By the time a product reaches this stage, it has already passed through smaller studies focused on safety and dosage, so the emphasis shifts firmly toward proving benefit across a broader, more representative patient population^[1].

The main purpose is to measure efficacy and to monitor adverse reactions. Because a Phase 3 trial is larger and longer than earlier phases, it is more likely to reveal side effects that are uncommon or that only appear after prolonged use. Most of the safety information collected before a treatment reaches the market comes from this phase. Not every treatment that enters Phase 3 will move forward afterwards. Roughly a quarter to a third of products that begin this phase are ultimately advanced. This reflects how demanding the combined efficacy and safety bar is at this stage. Put differently, a positive result in an earlier phase is encouraging, but it is not a guarantee; a substantial share of candidates still fall short once tested at this scale^[1].

How does a Phase 3 trial differ from Phase 1 and Phase 2?

A Phase 1 study enrols 20 to 100 people. These are often healthy volunteers, unless the drug is intended specifically for a condition such as cancer, in which case patients with that cancer take part instead. It runs for several months and focuses on safety and dosage. A Phase 2 study involves up to several hundred patients with the disease or condition, runs from several months to two years, and looks at efficacy and side effects, though it is not large enough on its own to prove a treatment benefit. Roughly a third of products that enter Phase 2 move on to the next stage of testing. This underlines how much attrition happens before a treatment is ever tested in a pivotal trial. Each phase, in other words, functions as a filter, and the population allowed through that filter is deliberately narrower and better characterised at every step^[1].

A Phase 3 study builds on the dosing and safety information from Phase 1 and Phase 2 and tests the treatment in a much larger, more diverse group of patients to confirm the benefit and detect rarer risks. Because Phase 1 and Phase 2 studies are relatively small, they are simply not statistically equipped to detect side effects that occur in, for example, 1 in 1,000 or 1 in 10,000 patients. A larger Phase 3 population, followed for up to four years, gives researchers a much better chance of observing those rarer or delayed reactions before the product is approved. This is also why the diversity of the Phase 3 population matters: patients differ in age, in the severity of their disease, and in the other medicines they take, and a trial that reflects that variety is more likely to produce results that generalise to everyday clinical practice^[1].

Phase	Participants	Length	Main purpose	Approximate proportion moving to the next phase
Phase 1	20–100 healthy volunteers or people with the disease/condition	Several months	Safety and dosage	~70%[1]
Phase 2	Up to several hundred people with the disease/condition	Several months to 2 years	Efficacy and side effects	~33%[1]
Phase 3	300–3,000 volunteers with the disease/condition	1–4 years	Efficacy and monitoring of adverse reactions	~25–30%[1]

Read across the three rows, the table shows a funnel: tens to low hundreds of participants in Phase 1, up to several hundred in Phase 2, and finally hundreds to thousands in Phase 3, with each stage adding months or years of observation. This progression explains why a treatment that looked promising in an early study can still fail later on. A small early trial can miss both modest efficacy problems and rare safety problems that only become visible once thousands of patients have been exposed to the treatment for a longer period. Seen this way, the funnel is not simply a matter of bureaucratic sequencing; it is a deliberate strategy for managing risk, since exposing thousands of patients to an unproven treatment before its basic safety profile is understood would be unacceptable^[1].

What does randomisation mean for the treatment you receive?

Randomised controlled trials evaluate at least two interventions — the test treatment and a control treatment — at the same time, across two or more study arms. Which arm a participant is placed in is decided by a random process, which is intended to keep the comparison free from bias. This design has been the standard against which other types of clinical trials are measured for decades. The logic behind randomisation is straightforward: if researchers, or patients themselves, chose which arm to join, people with a better or worse prognosis might end up unevenly distributed between groups. Any difference in outcomes could then reflect that imbalance rather than the treatment itself. This is why randomisation is applied across such a wide range of fields, from oncology to rehabilitation medicine to mental health, wherever researchers need a credible basis for saying that an observed difference was caused by the treatment rather than by who happened to receive it^[2].

In practice, this means that neither you nor, in many designs, your study team knows in advance which arm you have been assigned to. This is sometimes described as blinding, and it is used specifically to stop expectations — either yours or the researchers' — from influencing how symptoms are reported or assessed. If you are asked to join a Phase 3 trial, it is reasonable to ask the study team to explain how randomisation works for that specific protocol and whether a control treatment is used. Blinding is not always straightforward to achieve, particularly in trials involving physical devices, supervised exercise, or apps, and understanding how a specific protocol handles this can help you interpret your own experience within the study^[2].

What do Phase 3 and late-phase trials look like across different conditions?

Randomised trial designs are used across a wide range of conditions, from cancer to spinal cord injury to mental health, though the specific goals and comparison groups vary by field. What links these very different studies is not the disease being treated but the underlying method: participants are split into arms by chance, and the outcomes of those arms are compared against one another under a pre-specified protocol. The examples below, drawn from oncology, rehabilitation and cardiovascular-neurological conditions, infectious disease, and psychiatry, illustrate how differently that shared method can be applied depending on the clinical question at hand^[2].

Oncology

In oncology, a randomised Phase 2 trial in advanced esophageal squamous cell carcinoma compared a combination of ociperlimab and tislelizumab in patients with high PD-L1 expression, evaluating efficacy and safety in this specific patient subset. This illustrates how, before a Phase 3 confirmatory study is designed, earlier randomised trials are used to identify which biomarker-defined group of patients is most likely to benefit. Selecting a biomarker-defined population at an earlier phase, rather than testing an unselected group of patients directly in a large Phase 3 trial, is one way researchers try to increase the chance that a subsequent pivotal study will show a clear benefit. This approach also reduces the number of patients who need to be exposed to an experimental combination before its value in a defined subgroup is properly understood^[2].

Cardiology and neurology

Randomised designs are also used to test rehabilitation and physical interventions rather than only drugs. One example is a randomised trial protocol combining blood-flow-restricted exercise with spinal cord stimulation, delivered via telehealth, in people with tetraplegia. A separate meta-research study examined the statistical quality of randomised controlled trials of technology-based rehabilitation after spinal cord injury, which is a neurological condition with major cardiovascular and functional consequences. Because rehabilitation trials often combine a device, a supervised exercise programme, and a remote delivery method, they raise design questions that a simple drug-versus-placebo trial does not, such as how to blind participants to the intervention they are receiving. Telehealth delivery adds a further layer of complexity, since outcomes can be shaped as much by how consistently a participant engages with remote supervision as by the physiological effect of the intervention itself^[2].

Infectious disease example

A Phase 2 randomised controlled trial, called RIO, tested broadly neutralising antibodies in adult men living with HIV during a supervised pause in antiretroviral treatment, looking at how long viral rebound was delayed and whether resistance developed to the antibodies used. This is an example of a randomised design used to answer a very specific clinical question — delaying viral rebound — rather than a first-line efficacy question. A trial built around a supervised treatment pause also has to monitor participants closely for safety, since the intervention being tested is deliberately combined with a period of reduced background treatment. Trials of this kind depend on especially close coordination between the study team and participants, precisely because the study design temporarily removes part of the standard protection that ongoing antiretroviral treatment normally provides^[2].

Psychiatry and mental health

In mental health research, a commentary discusses why mental health apps frequently fail to outperform treatment control groups in randomised trials, arguing that this outcome is predictable given decades of broader research and does not automatically mean the apps do not work. The commentary notes that treatment controls remain the standard method for establishing whether such apps are effective, even though they can obscure part of the picture. A treatment control group is typically given something — attention, a placebo app, or a basic version of the intervention — rather than nothing at all. This can narrow the apparent gap between the active intervention and the comparison group even when the active intervention has a genuine, if modest, effect. This pattern is a useful reminder that a "negative" trial result does not always mean an intervention has no value; it may instead mean the comparison group was already receiving a reasonably effective alternative^[2].

What is different about clinical trials in older adults?

One example of a randomised trial focused on an older population is a pilot study of ResB supplementation and its effect on gut microbiome composition in elderly patients with pneumonia. This kind of pilot trial in an elderly population is typically smaller and earlier-phase than a pivotal Phase 3 study, and it is used to test feasibility and gather preliminary data before a larger trial is designed. A pilot of this kind is not intended to prove that a supplement changes clinical outcomes. Instead, it checks whether the intervention can be delivered as planned in a frail, elderly population, and whether early biological signals, such as changes in gut microbiome composition, are large enough to justify a bigger trial. This staged approach matters particularly in older populations, where frailty, multiple coexisting conditions, and polypharmacy can all affect how well an intervention is tolerated, well before a full-scale efficacy trial would be justified^[2].

If you are an older participant or the caregiver of one, it is worth asking the study team directly whether the trial protocol has been designed or adjusted with an older population in mind, since the sources reviewed here do not describe a separate, universal framework for this^[2].

Is artificial intelligence changing how Phase 3 and other trials are run?

A review outlines a framework in which artificial intelligence could support clinical trials through deeply phenotyped patient cohorts, validated surrogate endpoints, digital twins and agentic AI systems, with the aim of shortening trial timelines. The review states that any such approach needs to maintain rigorous regulatory and benefit-risk assessment. Tools such as digital twins are described as a way to model an individual patient's likely disease course, which could in principle help researchers identify a smaller, more precisely defined trial population, though the review is careful to frame this as a proposed framework rather than a settled practice. A separate commentary on one of the first randomised trials of AI in medicine argues that the next generation of medical AI should be judged on whether human-AI systems improve patient outcomes, not only on whether algorithms match clinicians. That distinction matters for future Phase 3 trials of AI-based tools, because it suggests the relevant comparison group may not simply be a human clinician working alone, but a human clinician supported by the AI system. Framed this way, these proposals do not replace randomisation or control groups; they are presented as ways to make the population entering a trial better characterised and the endpoints used to judge it more precise, while the underlying comparison still needs to be tested rigorously^[2].

What should you report to the study team during a Phase 3 trial?

Because Phase 3 trials are designed specifically to monitor adverse reactions, participants are expected to report any new or worsening symptom to the study team promptly, regardless of whether they believe it is related to the treatment. Longer trial duration and larger participant numbers in Phase 3 make it more likely that uncommon or delayed side effects are identified, but only if participants report symptoms as they occur. This is one of the practical reasons a trial can run for as long as four years: some adverse reactions simply take that long to accumulate enough cases to be recognised as a pattern rather than an isolated event. Every individual report, in that sense, contributes to a much larger dataset, and the value of that dataset depends heavily on how promptly and completely participants describe what they are experiencing^[1].

• Report any new symptom, even a mild one, to the study team rather than deciding on your own that it is unrelated;
• Keep a record of the date and time symptoms started, since Phase 3 studies formally track adverse reactions over the full one-to-four-year duration^[1];
• Ask which assessments are scheduled and when, since the study protocol defines this in advance^[1];
• Ask what happens if you want to stop taking part before the study ends.

When should you talk to your doctor or pharmacist about taking part in a Phase 3 trial?

Speak with your doctor or pharmacist before enrolling if you are taking other medicines, since the sources reviewed for this article do not describe how a specific trial protocol accounts for interactions with your existing treatment. Speak with the study team immediately, not only at your next scheduled visit, if you experience a new or worsening symptom after starting the study treatment, since Phase 3 studies are specifically designed to capture this information^[1]. Ask your doctor to help you understand whether you are in a trial arm receiving the test treatment or a control treatment, if the study design allows this information to be shared with you^[2]. It is also reasonable to ask your doctor how a Phase 3 trial's reported results, once published, might change your own treatment plan, since a pivotal trial's findings are what regulators use to decide whether a treatment becomes broadly available in the first place. These are not one-off conversations; as a trial progresses over months or years, it is worth revisiting these questions with your doctor or pharmacist whenever your own health status or medication list changes^[1].

Summary

A Phase 3 trial sits at the point in drug development where a treatment is tested in hundreds to thousands of patients over one to four years, specifically to confirm whether it works and to catch side effects that smaller, earlier studies could not detect^[1]. Randomisation and control groups are the tools researchers use to make that comparison fair, whether the trial is testing a cancer drug, a rehabilitation protocol after spinal cord injury, an antibody treatment for HIV, or a mental health app^[2].

Not every therapeutic area or population — including older adults — is represented by a uniform trial design, and the examples above show that randomised studies range from small pilot work to large pivotal trials. Emerging tools such as artificial intelligence are being proposed as ways to make these trials faster and more targeted, but the sources reviewed here stress that this cannot come at the expense of rigorous regulatory and benefit-risk assessment^[2]. If you are considering taking part in any of these studies, ask the study team directly about the phase, the size and length of the trial, and what reporting is expected of you as a participant^[1].

1. [1] U.S. Food and Drug Administration. Step 3: Clinical Research (accessed 2 June 2026) — https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
2. [2] Randomized controlled trials - Latest research and news (accessed 2 June 2026) — https://www.nature.com/subjects/randomized-controlled-trials